CRP and cardiovascular disorder: To further test the hypothesis that lipid-lowering medication interferes with anti-inflammatory effects of CRP, the BZATP-induced release of IL-1β by LPS-primed monocytes isolated from patients suffering from cardiovascular disease was investigated in the second part of this study.